ArticleClinical and translational allergy2023
Sensitivity to change and minimal clinically important difference of the angioedema control test.
Article in Clinical and translational allergy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Patient-Reported Outcomes in the Phase III OASIS-HAE Study of Donidalorsen for Hereditary Angioedema.Allergy · 2025Trial
- Lanadelumab Use for Hereditary Angioedema Long-Term Prophylaxis Over the Last 7 Years: A Narrative Review of Clinical and Real-World Data.Clinical reviews in allergy & immunology · 2026Review
- Sustained Effectiveness of Lanadelumab in Preventing Hereditary Angioedema Attacks: The ENABLE Study.Clinical and translational allergy · 2026Article
- Burden of Hereditary Angioedema in Adults: Impact of Disease and Patient Characteristics.International archives of allergy and immunology · 2026Article
- Quality of Life and Socioeconomic Situation of Patients with Hereditary Angioedema in Slovakia.Medicina (Kaunas, Lithuania) · 2026Article
- Association Between the Angioedema Control Test and Attack Frequency in Hereditary Angioedema.Clinical and translational allergy · 2026Article
- Donidalorsen for the Treatment of Hereditary Angioedema: A Review of Clinical Studies.Drug design, development and therapy · 2026Review
- A Treat-to-Target approach in hereditary angioedema: expert consensus from a European committee.Frontiers in immunology · 2026Article
- Observations on quality of life and disease control in patients with hereditary angioedema.Skin health and disease · 2025Article
- One-year real-life outcomes of lanadelumab therapy in Romanian patients with hereditary angioedema due to C1-inhibitor deficiency.Frontiers in allergy · 2025Article
- Disease control and disease activity in hereditary angioedema: two sides of the same coin?Frontiers in immunology · 2025Article
- Managing Hereditary Angioedema in a Three-Generation Family: Danazol's Promise in Resource-Limited Settings.Cureus · 2024Article
- [What are the main symptoms of urticaria and how are they systematically recorded?]Dermatologie (Heidelberg, Germany) · 2024Review
- Monitoring recurrent angioedema: Findings from the Turkish angioedema control test validation study.Clinical and translational allergy · 2024Article
- Berotralstat in hereditary angioedema due to C1 inhibitor deficiency: first real-world evidence from a Canadian center.Frontiers in immunology · 2024Article
- CRUSEClinical and translational allergy · 2024Article
- Sensitivity to change and minimal clinically important difference of the angioedema control test.Clinical and translational allergy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Angioedema Control Test (AECT) is a patient-reported outcome measure developed and validated for the assessment of disease control in patients with recurrent angioedema. Its sensitivity to change and minimal clinically important difference (MCID) have hitherto not been established.
methodsPatients with recurrent angioedema due to chronic spontaneous urticaria, hereditary angioedema, or acquired C1-inhibitor deficiency were repeatedly asked to complete the AECT along with the Angioedema Quality of Life Questionnaire (AE-QoL), Dermatology Life Quality Index (DLQI), and anchors for disease control and whether treatment was sufficient during routine care visits. The sensitivity to the change of the AECT was determined by correlating changes in its scores over time with changes in the applied anchors. The MCID was determined using anchor-based and distributional criterion-based approaches.
resultsEighty-six cases were used for this analysis. Changes in AECT scores correlated well with AE-QoL changes (but less with changes in the DLQI) as well as other applied anchors, demonstrating its sensitivity to change. The MCID was found to be three points for improvement of angioedema control. The available number of cases with meaningful deterioration in our dataset was too low to reach a definite conclusion on the MCID for deterioration of angioedema control.
conclusionThe AECT is a valuable tool to assess changes in disease control in patients with recurrent angioedema over time. The lowest AECT score change that reflects a meaningful improvement of disease control to patients (MCID) is three points.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.